The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

60% of those studies had no commercial or clinical utility ... For example, Merck [& Co.] has over 480 combination products ...

Merck (MRK) is set to announce Q3 earnings on October 31st. Analysts expect a profit of $1.57 per share on revenue of $16.51B ...

These approvals allow marketing of these Keytruda regimens for these indications in all 27 EU member states, as well as Iceland, Liechtenstein, Norway and Northern Ireland. Timing for commercial ...

Keytruda is now under threat not only from ... a further potential $1.7 billion in developmental, regulatory and commercial milestone payments. Other issues that affected performance were a ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...